Edgen Stock·Mar 31 2026, 15:02Key Takeaways:
Corning Jerry Pharmaceuticals (09966.HK) and CSPC Group (01093.HK) announced their jointly-developed drug KN026 met its primary endpoint in a Phase 3 trial for HER2-positive breast cancer, showing a significant improvement over standard treatments.
"The results have significant statistical and clinical implications," the companies said in a joint statement, noting the study achieved its pre-set primary endpoint of total pathological complete response rate, or tpCR.
The KN026-004 study evaluated KN026 combined with docetaxel as a neoadjuvant treatment for patients with HER2-positive breast cancer. The achievement of the tpCR endpoint indicates that a statistically significant portion of patients had no detectable cancer tissue remaining after the treatment course, a key measure of efficacy in this setting.
The positive data significantly de-risks the development of KN026 and positions it as a potentially best-in-class treatment, which could open up a major new revenue stream for both companies in the competitive oncology market.
The successful outcome of the Phase 3 trial is a critical milestone before the companies can seek regulatory approval for KN026. The companies confirmed that detailed data from the KN026-004 study will be presented at an upcoming international academic conference.
The disclosure of the full data set, including specific tpCR percentages and safety profiles, will be the next major catalyst for the drug's future. Investors and analysts will be closely watching for these details to fully assess the drug's market potential compared to existing therapies.
This article is for informational purposes only and does not constitute investment advice.
